zk1516841.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC  20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report: May 26, 2015

PLURISTEM THERAPEUTICS INC.
(Exact Name of Registrant as Specified in Its Charter)

Nevada
(State or Other Jurisdiction of Incorporation)

001-31392
98-0351734
(Commission File Number)
(IRS Employer Identification No.)

MATAM Advanced Technology Park
Building No. 5
Haifa, Israel
31905
(Address of Principal Executive Offices)
(Zip Code)
   

011 972 74 710 7171
(Registrant’s Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
Item 5.07.  Submission of Matters to a Vote of Security Holders.

Pluristem Therapeutics Inc. (the “Company”) held its annual meeting of stockholders on May 26, 2015. The results of the stockholder voting at the annual meeting are set forth below:

Proposal No. 1 — Election of directors

The stockholders elected the following individuals as directors of the Company to hold office until the next annual meeting of shareholders and until their successors shall have been duly elected and qualified.

Director Name
  
For
    
Against
    
Abstain
    
Broker Non-Votes
  
                                 
Zami Aberman
     14,372,479       3,769,809       80,283       15,304,893  
                                 
Israel Ben-Yoram
     14,569,794       3,399,867       252,910       15,304,893  
                                 
Isaac Braun
     14,576,543       3,389,915       256,113       15,304,893  
                                 
Mark Germain
     17,582,477       389,316       250,778       15,304,893  
                                 
Moria Kwiat
     17,341,338       627,549       253,684       15,304,893  
                                 
Hava Meretzki
     14,427,350       3,641,008       154,213       15,304,893  
                                 
Nachum Rosman
     17,528,436       444,934       249,201       15,304,893  
                                 
Doron Shorrer
     14,267,394       3,735,151       220,026       15,304,893  
                                 
Yaky Yanay
     12,594,972       5,545,570       82,029       15,304,893  

Proposal No. 2 — Approving, by a nonbinding advisory vote, the compensation of the Company's named executive officers
 
For
  
Against
  
Abstain
  
Broker Non-Votes
             
12,279,916
  
5,745,844
  
196,811
  
15,304,893
 
Proposal No. 3 — Ratification of the selection of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as independent registered public accounting firm of the Company for the fiscal year ending June 30, 2015

For
  
Against
  
Abstain
  
Broker Non-Votes
             
32,078,431
  
1,299,283
  
149,750
  
N/A
 
The results reported above are final voting results.

 
 
 
 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
PLURISTEM THERAPEUTICS INC.
  
     
Date: May 26, 2015
By:
/s/ Yaky Yanay
  
 
Name:
 Yaky Yanay
  
 
Title:
Chief Financial Officer, Secretary,
Chief Operating Officer and President